Lipid-Modifying Therapies and Stroke Prevention - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35554824/
doi: 10.1007/s11910-022-01197-4. Online ahead of print. 1 Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, Room 100K-2, Siebens Drake Bldg, 1400 Western Rd,...
Purpose of review: We reviewed lipid-modifying therapies and the risk of stroke and other cerebrovascular outcomes, with a focus on newer therapies.
Etiology and Management of Dyslipidemia in Patients With Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35548413/
Patients with cancer are now living longer than ever before due to the growth and expansion of highly effective antineoplastic therapies. Many of these patients face additional health challenges, of...
Conclusion: A contemporary cancer patient needs a personalized comprehensive cardiovascular assessment, management of lipid abnormalities, and prevention of late CVD to achieve optimal overall outcomes.
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
Source : https://www.tandfonline.com/doi/full/10.1080/07853890.2022.2059559
Abstract Abstract Atherosclerotic heart disease is the leading cause of mortality and morbidity in the USA. Low density lipoprotein (LDL) has been the target for many hypolipidemic agents to modify...
Conclusion: Given these results, bempedoic acid alone and in combination with ezetimibe received the USA FDA approval for adults with heterozygous familial hypercholesterolaemia or established atherosclerotic cardiovascular disease. We present a comprehensive review exploring the underlying mechanism, pre-clinical studies, and clinical trials...
What characterizes event-free elderly FH patients? A comprehensive lipoprotein profiling
Source : https://www.nmcd-journal.com/article/S0939-4753(22)00148-X/fulltext
Familial hypercholesterolemia (FH) is a genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C) and increased risk of premature coronary heart disease (CHD). Cholesterol-lowering therapy (statins) reduces CHD risk,...
Conclusion: CHD resistant elderly FH patients have higher levels of large HDL particles. The mechanisms behind the event-free survival among these patients remain unclear; hence, a deeper understanding of the metabolic profile in event-free elderly FH subjects may lead to development of novel preventive therapies.
Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35532248/
Familial hypercholesterolemia (FH) as a high-frequency genetic disorder is diagnosed based on family and/or patient's history of coronary heart disease (CHD) or some other atherosclerotic disease, LDL-C levels and/or clinical...
Conclusion: The cornerstone of medical therapy is the use of more potent statins in higher doses, to which often ezetimibe has to be added, but some FH patients do not achieve the target LDL-C with this therapy Therefore, besides these and the most recent but already established therapeutic approaches including PCSK9 inhibitors, inclisiran,...